Welcome back. Three signals this month: one on a sign already visible on a scan we already order, one on a complication that an older generation of clinicians knew well and a newer one is about to meet again, and one on a cheap old drug that does something real for the eye, though not quite what the headline will say.
— Nadège
In this Issue
A study in the *Indian Journal of Medical Research* (Vijay et al., November 2026) followed 428 people with non-healing diabetic foot ulcers who underwent diagnostic digital subtraction angiography at a tertiary diabetes centre. The investigators recorded wound blush — the contrast opacification of the ulcer bed itself, visible on the angiogram — and tracked outcomes through healing, minor amputation or major amputation. Across the cohort, 369 limbs were salvaged and 59 were lost. Wound blush status, before and after angioplasty, tracked with those outcomes closely enough that the authors argue angioplasty deserves a trial in these patients before bypass or amputation is considered.
This is observational work from a single centre, and wound blush is a qualitative read rather than a measurement. But the appeal of the finding is that it costs nothing new. The angiogram is already being done, the sign is already on the image, and what is proposed is that we read it as a prognosis rather than only as anatomy. For vascular surgeons, interventional radiologists and podiatry teams deciding how hard to push for revascularisation, that is a conversation worth having with the images already on the screen.
A systematic review and case series in the *Journal of Clinical Medicine* (9 November 2026) assembled 47 publications covering 219 patients with treatment-induced neuropathy of diabetes — an acute, painful small-fibre and autonomic neuropathy that follows rapid correction of chronic hyperglycaemia, classically a fall of more than two HbA1c percentage points within three months. The syndrome is not new; it was described generations ago as insulin neuritis. Painful neuropathy with autonomic dysfunction predominates, orthostatic hypotension is common, and it is reported more often in type 1 diabetes and in women. The two patients in the accompanying series, whose HbA1c fell by 15.3 and 6.4 percentage points, improved substantially over two years — but incompletely.
What makes an old syndrome worth reading about now is who is at risk of meeting it. GLP-1 and dual GIP/GLP-1 agonists are producing reductions in HbA1c, and in weight, at a scale and speed that were rare a decade ago, in far more patients. Case series have already described diabetic lumbosacral radiculoplexus neuropathy and common fibular neuropathy following GLP-1 exposure, and a matched case-control analysis found both associated with it. None of this argues against treating hyperglycaemia aggressively; the long-term case for glycaemic control is not in question. It argues for recognising the syndrome when it appears, rather than reading new neuropathic pain in a patient who is finally improving as a coincidence.
An updated systematic review and meta-analysis in *Diabetes Research and Clinical Practice* (Dogru et al., 14 November 2026) pooled four randomised trials and 20,655 participants on fenofibrate and diabetic retinopathy. The drug reduced the composite of retinopathy progression or need for retinal treatment (OR 0.67, 95% CI 0.56–0.81), incident macular oedema (0.47, 0.29–0.76) and the need for retinal laser (0.75, 0.65–0.87), with no heterogeneity between trials. Progression on imaging was reduced as well.
And then the part that will fall out of most summaries. Moderate vision loss did not differ (0.99, 0.83–1.18). Neither did all-cause mortality. Over up to five years, fenofibrate slows what the retinal images and the treatment registers record, without demonstrating that it preserves sight. Both halves of that sentence are worth carrying: a cheap, generic, decades-old lipid drug, prescribed largely by clinicians who never look at a retina, has a genuine effect on diabetic eye disease — and the endpoint patients actually care about has not yet moved.
OneGuild Pulse is a free monthly publication of OneGuild Institute. Forward freely.
Subscribe at oneguild.org/pulse.
— Nadège Sheehan, PhD
President, OneGuild Institute
New York, November 2026
Read the October letter · All letters